The DOI matches its Crossref record; 464 of the 464 references it cites were found in a registry or an index.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Abstract
BACKGROUND: Metformin is an oral anti-hyperglycemic agent that has been shown to reduce total mortality compared to other anti-hyperglycemic agents, in the treatment of type 2 diabetes mellitus. Metformin, however, is thought to increase the risk of lactic acidosis, and has been considered to be contraindicated in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age. OBJECTIVES: To assess the incidence of fatal and nonfatal lactic acidosis, and to evaluate blood lactate levels, for those on metformin treatment compared to placebo or non-metformin therapies. SEARCH STRATEGY: A comprehensive search was performed of electronic databases to identify studies of metformin treatment. The search was augmented by scanning references of identified articles, and by contacting principal investigators. SELECTION CRITERIA: Prospective trials and observational cohort studies in patients with type 2 diabetes of least one month duration were included if they evaluated metformin, alone or in combination with other treatments, compared to placebo or any other glucose-lowering therapy. DATA COLLECTION AND ANALYSIS: The incidence of fatal and nonfatal lactic acidosis was recorded as cases per patient-years, for metformin treatment and for non-metformin treatments. The upper limit for the true incidence of cases was calculated using Poisson statistics. In a second analysis lactate levels were measured as a net change from baseline or as mean treatment values (basal and stimulated by food or exercise) for treatment and comparison groups. The pooled results were recorded as a weighted mean difference (WMD) in mmol/L, using the fixed-effect model for continuous data. MAIN RESULTS: Pooled data from 347 comparative trials and cohort studies revealed no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use or in 55,451 patients-years in the non-metformin group. Using Poisson statistics the upper limit for the true incidence of lactic acidosis per 100,000 patient-years was 4.3 cases in the metformin group and 5.4 cases in the non-metformin group. There was no difference in lactate levels, either as mean treatment levels or as a net change from baseline, for metformin compared to non-metformin therapies. AUTHORS' CONCLUSIONS: There is no evidence from prospective comparative trials or from observational cohort studies that metformin is associated with an increased risk of lactic acidosis, or with increased levels of lactate, compared to other anti-hyperglycemic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedMeta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Statistical Methods for Rates and Proportions.
Plewis, I., & Fleiss, J. L. (1982) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2982107 · Cited by 1,731
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667
Clinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Turner, R., Cull, C., Holman, R., & United Kingdom Prospective Diabetes Study Group (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00011 · Cited by 465
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Cusi, K. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4059 · Cited by 455
Holman, R. R., Cull, C. A., & Turner, R. C. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.960 · Cited by 449
Metformin reduces systemic methylglyoxal levels in type 2 diabetes.
Beisswenger, P. J., Howell, S. K., Touchette, A. D., Lal, S., & Szwergold, B. S. (1999) · Diabetes · doi:10.2337/diabetes.48.1.198 · Cited by 446
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440
Chiasson, J.-L., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., Ryan, E. A., Tan, M. H., & Wolever*, T. M. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00004 · Cited by 436
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2008) · Diabetes Care · doi:10.2337/dc08-1171 · Cited by 426
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419
Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin
Bauman, W. A., Shaw, S., Jayatilleke, E., Spungen, A. M., & Herbert, V (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1227 · Cited by 412
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Lactic Acidosis in Patients with Diabetes Treated with Metformin
Misbin, R. I., Green, L., Stadel, B. V., Gueriguian, J. L., Gubbi, A., & Fleming, G. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380415 · Cited by 403
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385
Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 368
Eurich, D. T., McAlister, F. A., Blackburn, D. F., Majumdar, S. R., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2007) · BMJ · doi:10.1136/bmj.39314.620174.80 · Cited by 362
Lactate Homeostasis and Lactic Acidosis
KREISBERG, R. A. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-2-227 · Cited by 361
Nagi, D. K., & Yudkin, J. S. (1993) · Diabetes Care · doi:10.2337/diacare.16.4.621 · Cited by 353
Hermann, L. S., Scherstén, B., Bitzén, P.-O., Kjellström, T., Lindgärde, F., & Melander, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.10.1100 · Cited by 344
Incidence of lactic acidosis in metformin users.
Stang, M., Wysowski, D. K., & Butler-Jones, D. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.925 · Cited by 330
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Ahrén, B., Pacini, G., Foley, J. E., & Schweizer, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1936 · Cited by 309
Jadzinsky, M., Pfützner, A., Paz‐Pacheco, E., Xu, Z., Allen, E., Chen, R., & CV181‐039 Investigators (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01056.x · Cited by 296
Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293
Bastyr, E. J., Stuart, C. A., Brodows, R. G., Schwartz, S., Graf, C. J., Zagar, A., & Robertson, K. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1236 · Cited by 274
Schernthaner, G., Matthews, D. R., Charbonnel, B., Hanefeld, M., & Brunetti, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030861 · Cited by 268
Lactic acidosis in biguanide-treated diabetics: A review of 330 cases
Luft, D., Schm�lling, R. M., & Eggstein, M. (1978) · Diabetologia · doi:10.1007/bf01263444 · Cited by 262
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 260
Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients
Wu, M.-S., Johnston, P., Sheu, W.-H., Hollenbeck, C., Jeng, C.-Y., Goldfine, I., Chen, Y.-D., & Reaven, G. (1990) · Diabetes Care · doi:10.2337/diacare.13.1.1 · Cited by 257
Moses, R., Slobodniuk, R., Boyages, S., Colagiuri, S., Kidson, W., Carter, J., Donnelly, T., Moffitt, P., & Hopkins, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.119 · Cited by 248
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., Borger van der Burg, B., Donker, A. J. M., & Stehouwer, C. D. A. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01213.x · Cited by 244
Horton, E. S., Clinkingbeard, C., Gatlin, M., Foley, J., Mallows, S., & Shen, S. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1660 · Cited by 241
Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02191.x · Cited by 240
Simpson, S. H. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050748 · Cited by 235
Triple Therapy in Type 2 Diabetes
Rosenstock, J., Sugimoto, D., Strange, P., Stewart, J. A., Soltes-Rak, E., Dailey, G., & on behalf of the Insulin Glargine 4014 Study Investigators (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-0695 · Cited by 235
van der Meer, R. W., Rijzewijk, L. J., de Jong, H. W. A. M., Lamb, H. J., Lubberink, M., Romijn, J. A., Bax, J. J., de Roos, A., Kamp, O., Paulus, W. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.803916 · Cited by 233
Perriello, G., Misericordia, P., Volpi, E., Santucci, A., Santucci, C., Ferrannini, E., Ventura, M. M., Santeusanio, F., Brunetti, P., & Bolli, G. B. (1994) · Diabetes · doi:10.2337/diab.43.7.920 · Cited by 227
Avilés-Santa, L., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 225
Lactic Acidosis Rates in Type 2 Diabetes
Brown, J. B., Pedula, K., Barzilay, J., Herson, M. K., & Latare, P. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1659 · Cited by 223
Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00839.x · Cited by 223
DE JAGER, J., KOOY, A., LEHERT, P., BETS, D., WULFFELÉ, M. G., TEERLINK, T., SCHEFFER, P. G., SCHALKWIJK, C. G., DONKER, A. J. M., & STEHOUWER, C. D. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01420.x · Cited by 220
Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217
Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Nauck, M. A., Ellis, G. C., Fleck, P. R., Wilson, C. A., Mekki, Q., & for the Alogliptin Study 008 Group (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01933.x · Cited by 205
Mechanism of metformin action in non-insulin-dependent diabetes
Jackson, R. A., Hawa, M. I., Jaspan, J. B., Sim, B. M., DiSilvio, L., Featherbe, D., & Kurtz, A. B. (1987) · Diabetes · doi:10.2337/diab.36.5.632 · Cited by 202
U.K. Prospective Diabetes Study Group (1998) · Diabetes Care · doi:10.2337/diacare.21.1.87 · Cited by 202
High and typical 18F-FDG bowel uptake in patients treated with metformin
Gontier, E., Fourme, E., Wartski, M., Blondet, C., Bonardel, G., Le Stanc, E., Mantzarides, M., Foehrenbach, H., Pecking, A.-P., & Alberini, J.-L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0563-6 · Cited by 196
Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy
Imano, E., Kanda, T., Nakatani, Y., Nishida, T., Arai, K., Motomura, M., Kajimoto, Y., Yamasaki, Y., & Hori, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2135 · Cited by 196
Cook, M. N., Girman, C. J., Stein, P. P., Alexander, C. M., & Holman, R. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.995 · Cited by 187
Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
Johansen, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.33 · Cited by 186
Role of Metformin Accumulation in Metformin-Associated Lactic Acidosis
Lalau, J. D., Lacroix, C., Compagnon, P., Cagny, B. D., Rigaud, J. P., Bleichner, G., Chauveau, P., Dulbecco, P., Guérin, C., Haegy, J. M., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.779 · Cited by 185
Mellbin, L. G., Malmberg, K., Norhammar, A., Wedel, H., Ryden, L., & for the DIGAMI 2 Investigators (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm518 · Cited by 184
Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes
Natali, A., Baldeweg, S., Toschi, E., Capaldo, B., Barbaro, D., Gastaldelli, A., Yudkin, J. S., & Ferrannini, E. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1349 · Cited by 181
Re-evaluation of a biguanide, metformin: mechanism of action and tolerability
Sirtori, C. (1994) · Pharmacological Research · doi:10.1016/1043-6618(94)80104-5 · Cited by 177
Matthews, D. R., Charbonnel, B. H., Hanefeld, M., Brunetti, P., & Schernthaner, G. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.478 · Cited by 175
Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., Borger van der Burg, B., Donker, A. J. M., & Stehouwer, C. D. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2133 · Cited by 175
Grant, P. J. (1996) · Diabetes Care · doi:10.2337/diacare.19.1.64 · Cited by 173
Bosi, E., Dotta, F., Jia, Y., & Goodman, M. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01040.x · Cited by 173
Evaluation of Prescribing Practices: Risk of Lactic Acidosis With Metformin Therapy
Calabrese, A. T., Coley, K. C., DaPos, S. V., Swanson, D., & Rao, R. H. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.4.434 · Cited by 170
Giugliano, D., Quatraro, A., Consoli, G., Minei, A., Ceriello, A., De Rosa, N., & D'Onofrio, F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315466 · Cited by 169
Sambol, N. C., Chiang, J., O'Conner, M., Liu, C. Y., Lin, E. T., Goodman, A. M., Benet, L. Z., & Karam, J. H. (1996) · The Journal of Clinical Pharmacology · doi:10.1177/009127009603601105 · Cited by 167
Panahloo, A., Mohamed-Ali, V., Lane, A., Green, F., Humphries, S. E., & Yudkin, J. S. (1995) · Diabetes · doi:10.2337/diab.44.1.37 · Cited by 167
Biguanide-Associated Lactic Acidosis: Case Report and Review of the Literature
Gan, S. C. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.11.2333 · Cited by 166
Charpentier, G., Fleury, F., Kabir, M., Vaur, L., & Halimi, S. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00582.x · Cited by 166
Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021786 · Cited by 163
Effect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitus
Scarpello, J. H. B., Hodgson, E., & Howlett, H. C. S. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8<651::aid-dia628>3.0.co;2-a · Cited by 160
Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Gottschalk, M. E., Danne, T., Vlajnic, A., & Cara, J. F. (2007) · Diabetes Care · doi:10.2337/dc06-1554 · Cited by 159
Şahin, M., Tütüncü, N. B., Ertuğrul, D. T., Tanaci, N., & Guvener, N. D. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.10.005 · Cited by 154
Johnson, A. B., Webster, J. M., Sum, C. F., Heseltine, L., Argyraki, M., Cooper, B. G., & Taylor, R. (1993) · Metabolism · doi:10.1016/0026-0495(93)90284-u · Cited by 154
Cryer, D. R., Nicholas, S., Henry, D. H., Mills, D. J., & Stadel, B. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.539 · Cited by 150
Hoffmann, J., & Spengler, M. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00252-0 · Cited by 148
Schwartz, S. L., Fonseca, V. A., Berner, B., Cramer, M., Chiang, Y.-K., & Lewin, A. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1967 · Cited by 147
Robinson, A. C., Burke, J., Robinson, S., Johnston, D. G., & Elkeles, R. S. (1998) · Diabetes Care · doi:10.2337/diacare.21.5.701 · Cited by 146
Garber, A. J., Larsen, J. L., Schneider, S. H., Piper, B. A., Henry, D. A., & The Glyburide/Metformin Initial Therapy Study Group (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00211.x · Cited by 144
Contraindications to Metformin Therapy in Patients With NIDDM
Sulkin, T., Bosman, D., & Krentz, A. J. (1997) · Diabetes Care · doi:10.2337/diacare.20.6.925 · Cited by 143
Ciaraldi, T. P., Kong, A. P. S., Chu, N. V., Kim, D. D. H., Baxi, S. C., Loviscach, M., Plodkowski, R. A., Reitz, R. E., Caulfield, M. P., Mudaliar, S. R. D., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.1.30 · Cited by 141
Brazg, R., Xu, L., Man, C. D., Cobelli, C., Thomas, K. A., & Stein, P. P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00691.x · Cited by 137
Rachmani, R., Slavachevski, I., Levi, Z., Zadok, B.-S., Kedar, Y., & Ravid, M. (2002) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(02)00131-0 · Cited by 134
Metabonomic Variations in the Drug-Treated Type 2 Diabetes Mellitus Patients and Healthy Volunteers
Bao, Y., Zhao, T., Wang, X., Qiu, Y., Su, M., Jia, W., & Jia, W. P. (2009) · Journal of Proteome Research · doi:10.1021/pr800643w · Cited by 134
Williams‐Herman, D., Johnson, J. R., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802705679 · Cited by 134
Contra‐indications to metformin therapy are largely disregarded
Holstein, A., Nahrwold, D. A., Hinze, S., & EGBERTS, E. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00115.x · Cited by 133
Lalau, J., & Race, J.-M. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00128.x · Cited by 131
Kim, Y., Ciaraldi, T. P., Kong, A. P. S., Kim, D. S., Chu, N. V., Mohideen, P., Mudaliar, S. R. D., Henry, R. R., & Kahn, B. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2.443 · Cited by 129
Schweizer, A., Dejager, S., & Bosi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01051.x · Cited by 128
The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients
Ersoy, C., Kiyici, S. K., Budak, F., Oral, H. B., Güçlü, M., Duran, C., Selimoğlu, H., Ertürk, E., Tuncel, E., & İmamoğlu, Ş. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.02.006 · Cited by 127
Galuska, D., Nolte, L. A., Zierath, J. R., & Wallberg‐Henriksson, H. (1994) · Diabetologia · doi:10.1007/bf00404340 · Cited by 126
Metformin-associated lactic acidosis in Sweden 1977–1991
Wiholm, B. ‐., & Myrhed, M. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf02440866 · Cited by 124
Nauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M. N., & Balena, R. (2009) · Diabetes Care · doi:10.2337/dc08-1961 · Cited by 122
Strowig, S. M., Avilés-Santa, L. M., & Raskin, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1691 · Cited by 122
Monami, M., Luzzi, C., Lamanna, C., Chiasserini, V., Addante, F., Desideri, C. M., Masotti, G., Marchionni, N., & Mannucci, E. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.642 · Cited by 121
Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
Campbell, I. W., & Howlett, H. C. S. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110509 · Cited by 121
Effect of Metformin on Postprandial Lipemia in Patients With Fairly to Poorly Controlled NIDDM
Jeppesen, J., Zhou, M., Chen, Y. I., & Reaven, G. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.10.1093 · Cited by 119
Berne, C., & the Orlistat Swedish Type 2 diabetes Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01474.x · Cited by 119
Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes
Nielsen, O. H., Schmitz, O., Andersen, P. H., Beck‐Nielsen, H., & Pedersen, O. B. (1989) · European Journal of Endocrinology · doi:10.1530/acta.0.1200257 · Cited by 118
Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., & Ridker, P. M. (2009) · JAMA · doi:10.1001/jama.2009.1347 · Cited by 117
Gerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116
Hsu, C.-H., Liao, Y.-L., Lin, S.-C., Hwang, K., & Chou, P. (2007) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2006.6054 · Cited by 114
Kann, P., Wascher, T. C., Zackova, V., Moeller, J., Medding, J., Szöcs, A., Mokáň, M., Mrevlje, F., & Regulski, M. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-949655 · Cited by 111
Yu, J., Kruszynska, Y. T., Mulford, M. I., & Olefsky, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2414 · Cited by 110
Chow, C., Tsang, L. W. W., Sorensen, J. P., & Cockram, C. S. (1995) · Diabetes Care · doi:10.2337/diacare.18.3.307 · Cited by 110
Stocker, D. J., Taylor, A. J., Langley, R. W., Jezior, M. R., & Vigersky, R. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.11.005 · Cited by 109
Nosadini, R., Avogaro, A., Trevisan, R., Valerio, A., Tessari, P., Duner, E., Tiengo, A., Velussi, M., Prato, S. D., de Kreutzenberg, S., et al. (1987) · Diabetes Care · doi:10.2337/diacare.10.1.62 · Cited by 109
Slama, G., Jean-Joseph, P., Goicolea, I., Elgrably, F., Haardt, M. J., Costagliola, D. G., Bornet, F. R. J., & Tchobroutsky, G. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91045-6 · Cited by 109
Clarke, B. F., & Duncan, L. J. P. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92726-8 · Cited by 108
Fisman, E. Z., Tenenbaum, A., Adler, Y., Motro, M., Boyko, V., Benderly, M., FRIEDENSOHN, A., Kohanovski, M., Rotzak, R., Schneider, H., et al. (2001) · Clinical Cardiology · doi:10.1002/clc.4960240210 · Cited by 107
Oral antidiabetic combination therapy with sulphonylureas and metformin.
Haupt, E., Knick, B., Koschinsky, T., Liebermeister, H., Schneider, J., & Hirche, H. (1991) · PubMed · Cited by 107
The Effect of Intravenous Metformin on Glucose Metabolism During Hyperglycaemia in Type 2 Diabetes
Sum, C. ‐., Webster, J. M., Johnson, A. B., Catalano, C., Cooper, B. G., & Taylor, R. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01716.x · Cited by 103
Yale, J., Valiquett, T. R., Ghazzi, M. N., Owens-Grillo, J. K., Whitcomb, R. W., Foyt, H. L., & for the Troglitazone Triple-Therapy Study Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-9_part_1-200105010-00010 · Cited by 102
Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C. G., Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U., Pedersen, O. B., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0815 · Cited by 101
Effects of Sibutramine in Obese Female Subjects With Type 2 Diabetes and Poor Blood Glucose Control
Gökçel, A., Karakose, H., Ertörer, M. E., Tanaci, N., Tütüncü, N. B., & Guvener, N. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1957 · Cited by 100
Chiasson, J., & Naditch‐Brûlé, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.989 · Cited by 100
Groop, L., Wid�n, E., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Schalin, C., & Eriksson, J. G. (1989) · Diabetologia · doi:10.1007/bf00285334 · Cited by 99
McIntyre, D. H., Paterson, C. A., Ma, A., Ravenscroft, P. J., Bird, D., & Cameron, D. P. (1991) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1991.tb01375.x · Cited by 98
Cacciapuoti, F., Spiezia, R., Bianchi, U., Lama, D., D’Avino, M., & Varricchio, M. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90617-t · Cited by 96
Reaven, G. M., Johnston, P., Hollenbeck, C. B., Skowroński, R., Zhang, J. C., Goldfine, I. D., & Chen, Y. I. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1569149 · Cited by 96
Herman, G. A., Bergman, A. J., Yi, B., Kipnes, M. S., & for the Sitagliptin Study 012 Group (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132587 · Cited by 96
Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.
Prager, R., Schernthaner, G.-H., & Graf, H. (1986) · PubMed · Cited by 96
Lawrence, J. M., Reid, J., Taylor, G. T., Stirling, C., & Reckless, J. P. D. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.41 · Cited by 95
Teranishi, T., Ohara, T., Maeda, K., Zenibayashi, M., Kouyama, K., Hirota, Y., Kawamitsu, H., Fujii, M., Sugimura, K., & Kasuga, M. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.005 · Cited by 94
Metformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes
Pagano, G., Tagliaferro, V., Carta, Q., Caselle, M. T., Bozzo, C., Vitelli, F., Trovati, M., & Cocuzza, E. (1983) · Diabetologia · doi:10.1007/bf00251823 · Cited by 94
The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?
Peacock, I., & Tattersall, R. B. (1984) · BMJ · doi:10.1136/bmj.288.6435.1956 · Cited by 94
Lessons from UK prospective diabetes study
Turner, R. C., & Holman, R. R. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01105-m · Cited by 94
Efficacy and Safety of Acarbose in Metformin-Treated Patients With Type 2 Diabetes
Rosenstock, J., Brown, A., Fischer, J., Jain, A., Littlejohn, T., Nadeau, D., Sussman, A., Taylor, T., Krol, A., & Magner, J. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2050 · Cited by 93
Garber, A. J., KLEIN, E. J., BRUCE, S. R., Sankoh, S., & Mohideen, P. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00570.x · Cited by 93
Göke, B., Hershon, K. S., Kerr, D. E., Pascual, A. C., Schweizer, A., Foley, J. E., Shao, Q., & Dejager, S. (2008) · Hormone and Metabolic Research · doi:10.1055/s-0028-1082334 · Cited by 93
Hussain, S. A., Khadim, H. M., Khalaf, B. H., Ismail, S. H., Hussein, K. I., & Sahib, A. S. (2006) · Saudi Medical Journal · doi:10.15537/1658-3175.3618 · Cited by 93
Karlsson, H., Hällsten, K., Björnholm, M., Tsuchida, H., Chibalin, A., Virtanen, K. A., Heinonen, O. J., Lönnqvist, F., Nuutila, P., & Zierath, J. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1459 · Cited by 92
Marre, M., Howlett, H. C. S., Lehert, P., & Allavoine, T. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00774.x · Cited by 92
Clarke, B. F., & Campbell, I. W. (1977) · BMJ · doi:10.1136/bmj.2.6102.1576 · Cited by 91
Gao, Y., Yoon, K., Chuang, L., Mohan, V., Ning, G., Shah, S., Jang, H. C., Wu, T.-J., Johns, D., Northrup, J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.037 · Cited by 91
Epidemiology of adverse drug reactions to phenformin and metformin.
Bergman, U., Boman, G., & Wiholm, B. ‐. (1978) · BMJ · doi:10.1136/bmj.2.6135.464 · Cited by 91
Nar, A., & Gedik, O. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0067-2 · Cited by 90
Manzella, D. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.11.006 · Cited by 89
Formoso, G., Filippis, E. A. D., Michetti, N., Fulvio, P. D., Pandolfi, A., Bucciarelli, T., Ciabattoni, G., Nicolucci, A., Davì, G., & Consoli, A. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.794 · Cited by 87
Faure, P., Wiernsperger, N. F., Polge, C., Favier, A. E., & Halimi, S. (2008) · Clinical Science · doi:10.1042/cs20070276 · Cited by 86
Hermann, L. S., Scherstén, B., & Melander, A. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00253.x · Cited by 86
Janka, H. U., Plewe, G., & Busch, K. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01043.x · Cited by 85
One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.
Campbell, I. W., Menzies, D. G., Chalmers, J., McBain, A. M., & Brown, I. R. F. (1994) · PubMed · Cited by 85
Metformin and the sulphonylureas: the comparative risk.
Campbell, I. W. (1985) · PubMed · Cited by 85
Tessier, D., Maheux, P., Khalil, A., & Fülöp, T. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90226-3 · Cited by 84
Jung, H. S., Youn, B., Cho, Y. M., Yu, K.-Y., Park, H. J., Shin, C. S., Kim, S. Y., Lee, H. K., & Park, K. S. (2005) · Metabolism · doi:10.1016/j.metabol.2004.05.019 · Cited by 83
Umpierrez, G. E., Issa, M., & Vlajnic, A. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x104786 · Cited by 83
Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients
Gin, H., Messerchmitt, C., Brottier, E., & Aubertin, J. (1985) · Metabolism · doi:10.1016/0026-0495(85)90139-8 · Cited by 82
Derosa, G., D’Angelo, A., Ragonesi, P. D., Ciccarelli, L., Piccinni, M. N., PRICOLO, F., SALVADEO, S. A. T., Montagna, L., Gravina, A., Ferrari, I., et al. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00756.x · Cited by 82
Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM Patients
Chan, J. C. N., Tomlinson, B., Critchley, J., Cockram, C. S., & Walden, R. (1993) · Diabetes Care · doi:10.2337/diacare.16.7.1035 · Cited by 81
Douek, I. F., Allen, S., Ewings, P., Gale, E. A. M., Bingley, P. J., & for the Metformin Trial Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01475.x · Cited by 79
Metformin Improves Hemodynamic and Rheological Responses to L-Arginine in NIDDM Patients
Marfella, R., R, A., Verrazzo, G., Ziccardi, P., Rosa, N. D., Giunta, R. E., & Giugliano, D. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.934 · Cited by 79
Amador‐Licona, N., Guízar-Mendoza, J., Vargas, E., Sánchez-Camargo, G., & Zamora-Mata, L. (2000) · Archives of Medical Research · doi:10.1016/s0188-4409(00)00241-1 · Cited by 78
Willms, B., & Ruge, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00149.x · Cited by 77
Grant, P. J., Stickland, M. H., Booth, N. A., & Prentice, C. R. M. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01610.x · Cited by 77
Long-Term Efficacy of Metformin Therapy in Nonobese Individuals With Type 2 Diabetes
Ong, C. R., Molyneaux, L. M., Constantino, M., Twigg, S. M., & Yue, D. K. (2006) · Diabetes Care · doi:10.2337/dc06-0827 · Cited by 77
The Effect of Glibenclamide and Metformin on Serum Lipoproteins in Type 2 Diabetes
Rains, S. G. H., Wilson, G. A., Richmond, W., & Elkeles, R. S. (1988) · Diabetic Medicine · doi:10.1111/j.1464-5491.1988.tb01074.x · Cited by 76
Yamanouchi, T., Sakai, T., Igarashi, K., Ichiyanagi, K., Watanabe, H., & Kawasaki, T. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01656.x · Cited by 76
Goodman, M., Thurston, H. J., & Penman, J. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0028-1104604 · Cited by 75
for the OBDM-002 Study Group, Toplak, H., Hamann, A., Moore, R., Masson, E., Górska, M., Vercruysse, F., Sun, X., & Fitchet, M. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803382 · Cited by 75
Bayraktar, M., Thiel, D. H. V., & Adalar, N. (1996) · Diabetes Care · doi:10.2337/diacare.19.3.252 · Cited by 75
Ceriello, A., Johns, D., Widel, M., Eckland, D. J. A., Gilmore, K. J., & Tan, M. H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.266 · Cited by 75
The Effects of Metformin and Diet on Plasma Testosterone and Leptin Levels in Obese Men
Özata, M., Öktenli, Ç., Bingöl, N., & Ozdemír, I. C. (2001) · Obesity Research · doi:10.1038/oby.2001.90 · Cited by 74
Double-Blind Evaluation of Efficacy and Tolerability of Metformin in NIDDM
Dornan, T., Heller, S. R., Peck, G. M., & Tattersal, R. B. (1991) · Diabetes Care · doi:10.2337/diacare.14.4.342 · Cited by 73
Bailey, C. J., Bagdonas, A., Rubes, J., McMorn, S. O., Donaldson, J., Biswas, N., & Stewart, M. W. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.012 · Cited by 73
Fujioka, K., Brazg, R. L., Raz, I., Bruce, S., Joyal, S., Swanink, R., & Pans, M. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00369.x · Cited by 73
Lalor, B., Bhatnagar, D., Winocour, P. H., Ishola, M., Arrol, S., Brading, M., & Durrington, P. N. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01378.x · Cited by 73
Blonde, L., Rosenstock, J., Mooradian, A. D., Piper, B. A., & Henry, D. A. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00229.x · Cited by 72
Sulphonylurea Failure in Type 2 Diabetes: Treatment with a Basal Insulin Supplement
Holman, R. R., Steemson, J., & Turner, R. C. (1987) · Diabetic Medicine · doi:10.1111/j.1464-5491.1987.tb00909.x · Cited by 72
Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin
Abbasi, F., Carantoni, M., Chen, Y. D. I., & Reaven, G. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1301 · Cited by 72
Research works printed but not linked: 44
- Abbink, 2000, Vascular effects of glibenclamide, glimepiride, metformin and acarbose in Type 2 DM patients, Diabetologia, 43, A39
- Andras, 1962, [Experience with biguanide treatment for diabetes mellitus], Orvosi hetilap, 103, 1029
- Bacci, 1961, [N.N. dimethyl-biguanide (DMGG) in the treatment of Diabetes meliitus], Minerva Medica, 52, 2770
- Boronat, 2000, [Effectiveness of treatment with metformin in patients with type 2 diabetes mellitus poorly controlled with insulin treatment], Revista Clinica Espanola, 200, 74
- Botha, 1977, Association of lactic acidosis with biguanide therapy [letter], South African Medical Journal, 52, 301
- Campbell, 1988, Effects of metformin on blood pressure and microalbuminuria in diabetes mellitus, Diabete & Metabolisme, 14, 613
- Canivet, 1962, [The treatment of Diabetes mellitus: Statistical results after a review of 1190 cases], La Presse Medicale, 70, 2038
- Davidson, 2000, Effect of metformin/glyburide tablets on HBA1c in first-line treatment of Type 2 Diabetes, Diabetologia, 43, A184
- DeFronzo, 1993, Combined metformin/glyburide treatment in NIDDM patients not optimally responding to maximum dose sulfonyluria: Results of a multicenter trial., Diabetes, 42, 146A (abs 455)
- 1993, Efficacy and safety of metformin in NIDDM: Results of a muticenter trial, Diabetes, 42, Abs 178
- Dornan, 1988, Metformin monotherapy for obese non-insulin-dependent diabetes. A double-blind evaluation, Diabetic Medicine, 5, 5 (Abs A17)
- Eriksson, 2007, Short-term effects of metformin in type 2 diabetes, Diabetes, Obesity & Metabolism, 9, 483, 10.1111/j.1463-1326.2006.00624.x · DOI
- Ferner, 1988, Impaired beta-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes, Quarterly Journal of Medicine, 66, 137
- Gursoy, 2000, The effect of metformin on insulin resistance and serum lipid profiles, Diabetologia, 43, A150
- Herman, 1961, Dimethyldiguanide (Glucophage, LA 6023) in Diabetes mellitus, South African Medical Journal, 35, 286
- Hu, 2008, [Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study]. [Chinese], Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering, 25, 682
- Jackson, 1962, Combined oral therapy in Diabetes, South African Medical Journal, 36, 727
- Jones, 2000, Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin, Diabetologia, 43, A192
- Jones, 2000, Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with Type 2 Diabetes, Diabetologia, 43, A191
- Kooy, 2009, Increase in value of adding metformin to insulin therapy in type 2 diabetes: More favorable weight with less macrovascular complications, Nederlands Tijdschrift voor Geneeskunde, 153, 1005
- Marena, 1994, Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes [see comments], Diabete & Metabolisme, 20, 15
- Mughal, 2000, The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabtic patients with sub-optimal metabolic control, Journal of the Pakistani Medical Association, 50, 381
- Pirart, 1961, [A new oral antidiabetic medicine: N.N. Dimethylbiguanide. Clinical trial alternating a placebo with a sulfamide], Acta Clinica Belgica, 16, 575
- Siedradzki, 1999, [Assessment of efficacy and safety of acarbose in the treatment of diabetes mellitus. Observation study in the conditions of general health care], Przeglad Lekarski, 56, 335
- Sterne, 1963, [Report on five years experience with Metformin], Wiener Medizinische Wochenschrift, 113, 599
- Stratmann, 1965, [Experience with Dimethylbiguanide in late failrues of oral diabetes therapy], Medizinische Welt, 49, 2743
- Wulffele, 2000, Metformin and insulin therapy decreases glycosylated hemoglobin and insulin requirement in Type 2 Diabetes, Diabetologia, 43, A184
- Debry, 1964, [Study of lactic acid levels on an empty stomach in diabetic patients treated with N-N-dimethylbiguanide], Diabete, 12, 239
- Debry, 1966, [Results of the treatment of Diabetes mellitus in the adult with the association of Metformin and sulfamides (concerning 197 cases)], Journal de Medicine de Lyon, 47, 407
- Debry, 1966, [Results of the treatment of Diabetes mellitus in the adult with metformin (concerning 202 cases0], Journal de Medicine de Lyon, 47, 395
- Isnard, 1996, [Long term treatment with biguanides in the natural evolution of non-insulin-dependent diabetes], Journ Annu Diabetol Hotel Dieu, 273
- Javaid, 2007, A comparative study of the effects of hypogycemic agents on serum electrolutes in the diabetic patients, Pakistani Journal of Pharmacological Science, 20, 67
- Lalau, 1994, Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis, Nephrology Dialysis and Transplantation, 9, 126
- Lapina, 2008, [Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure"]. [Russian], Kardiologiia, 48, 58
- Messens, 1966, [Treatment of diabetes mellitus with N.N. dimethy-biguanide], Diabete, 14, 74
- Muntoni, 1965, [Dimethyl-biguanide in the treatment of diabetes mellitus], La Clinica terapeutica, 35, 227
- O'Connor, 1998, Care of adults with type 2 diabetes mellitus. A review of the evidence [see comments], Journal of Family Practice, 47, S13
- Orlikowska, 1966, [Influence of N.N. dimethyl biguandie on certain elements of lipid metabolism in diabetic patients], Le Diabete, 14, 183
- Rambert, 1961, [Treatment of diabetes mellitus with NN-dimethyl-diguanide. Experience of 177 cases], Semaine des Hospitaux de Paris, 37, 247
- Sharabashi, 2006, Retrospecitve review of metformin in inpatients and outpatients at the University of Michigan, Diabetes Care, 29, 170, 10.2337/diacare.29.01.06.dc05-1762 · doi:10.2337/diacare.29.01.06.dc05-1762
- Teitelbaum, 1963, [Biguanides and sulfamides in small doses in the initial treatment of diabetes in obese patients], Diabete, 11, 342
- 1999, Metformin hydrochloride, 2755
- Olivia, 1970, Lactic acidosis, American Journal of Medicine, 48, 208
- Sterne, 1959, [Treatment of Diabetes mellitus with N.N. Dimethyl Guanil Guanidine (LA 6023, glucophage)], Therapie, 14, 625
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., Kurella Tamura, M., & Feldman, H. I. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.416 · Cited by 1,779
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Metadata
- Authors
- Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-01-20
- Issue
- 1
- Pages
- CD002967-CD002967
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4233394038
- Cited by
- 434
- References
- 464
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.